{
    "clinical_study": {
        "@rank": "87268", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (starch, magnesium stearate, citric acid) capsules once daily for 4 weeks."
            }, 
            {
                "arm_group_label": "B. subtilis R0179 (10 billion CFU)", 
                "arm_group_type": "Experimental", 
                "description": "B. subtilis R0179 (approximately 10 billion CFU/capsule) once daily for 4 weeks."
            }, 
            {
                "arm_group_label": "B. subtilis R0179 (1 billion CFU)", 
                "arm_group_type": "Experimental", 
                "description": "B. subtilis R0179 (approximately 1 billion CFU/capsule) once daily for 4 weeks."
            }, 
            {
                "arm_group_label": "B. subtilis R0179 (0.1 billion CFU)", 
                "arm_group_type": "Experimental", 
                "description": "B. subtilis R0179 (approximately 0.1 billion CFU/capsule) once daily for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of three doses of the probiotic B.\n      subtilis (Bacillus subtilis R0179) delivered in capsules on gastrointestinal and general\n      wellness in healthy young adults, survival through the gastrointestinal tract and impact on\n      intestinal microbes."
        }, 
        "brief_title": "Evaluation of Bacillus Subtilis R0179 in Healthy Young Adults", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "A 6 week randomized, double blind placebo controlled trial in healthy young adults aged 18\n      to 50. Participants will be administered an oral dose of B. subtilis or placebo (1\n      capsule/day) for a period of 4 weeks. Viable counts will be measured from stool samples to\n      assess transit survival, daily questionnaires will be administered to assess general\n      wellness and gastrointestinal (GI) symptoms will be evaluated three times with a validated\n      GI symptom questionnaire."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: Participants\n\n          -  Are 18-50 years of age\n\n          -  Are willing and able to complete the Informed Consent Form in English\n\n          -  Are willing to complete the GPAQ (Global Physical Activity Questionnaire) at baseline\n             and during the last week of the study as well as completing the GSRS\n             (Gastrointestinal Symptom Response Survey) questionnaire at baseline, during\n             treatment and post treatment\n\n          -  Are currently \"moderately active\" as determined by the GPAQ (Global Physical Activity\n             Questionnaire)\n\n          -  Are willing to have height and weight measured and to provide demographic information\n             (age, race, sex)\n\n          -  Are willing to consume B. subtilis R0179 (approximate doses of 1, 10, or 0.1 billion\n             CFU per day) or placebo for a 28 day period by capsule (1 per day)\n\n          -  Are willing to complete daily questionnaires regarding general and gastrointestinal\n             wellness for the duration of the study\n\n          -  Are willing to provide 1 stool at baseline, 1 stool during week 4 of the treatment\n             and 1 stool after 7 days of washout\n\n          -  Are willing to provide a social security number to receive study payment. Note: the\n             subject can still participate if unwilling to provide social security number, but no\n             financial reimbursement can be provided\n\n          -  Are willing to have internet access for the duration of the study\n\n        Exclusion Criteria: Potential Participants will be excluded if they\n\n          -  Do not meet the inclusion criteria\n\n          -  Are currently taking medications for constipation or diarrhea\n\n          -  Have taken antibiotics within the past four weeks prior to randomization\n\n          -  Are currently taking probiotics supplements and do not want to discontinue a minimum\n             of two weeks prior to the study\n\n          -  Known to have or are currently being treated for any diseases or illnesses such as\n             gastrointestinal disease (gastric ulcers, Crohn's, ulcerative colitis, etc.), other\n             chronic diseases (diabetes, kidney disease, etc.) or immune-compromising diseases or\n             conditions (HIV, AIDS, autoimmune, hepatitis, cancer, transplant patient etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "81", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802151", 
            "org_study_id": "177-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "B. subtilis R0179 (10 billion CFU)", 
                    "B. subtilis R0179 (1 billion CFU)", 
                    "B. subtilis R0179 (0.1 billion CFU)"
                ], 
                "description": "B. subtilis R0179 for a period of 4 weeks. One capsule per day.", 
                "intervention_name": "B. subtilis R0179", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "B. subtilis R0179"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "probiotics", 
            "microbiota", 
            "survival", 
            "gastrointestinal", 
            "wellness"
        ], 
        "lastchanged_date": "February 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32611"
                }, 
                "name": "University of Florida"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Evaluation of Bacillus Subtilis R0179 in Capsules on Gastrointestinal Survival, Transit Time, Gastrointestinal Symptoms, and General Wellness in Healthy Young Adults", 
        "overall_official": [
            {
                "affiliation": "University of Florida", 
                "last_name": "Wendy J Dahl, PhD, RD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Florida", 
                "last_name": "Bobbi Henken-Langkamp, PhD, RD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Florida", 
                "last_name": "Volker Mai, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Questionnaires administered to participants nightly evaluated a broad range of general wellness symptoms on a scale of 0 (no symptom present) to 6 (very severe).\nGastrointestinal Symptom Questionaires were administered at baseline (week 1), end of treatment (week 5), and washout (post week 6) to evaluate the presence or absence of gastrointestinal symptoms.  Scale ranged from 1 (no discomfort at all) to 7 (very severe).", 
            "measure": "Evaluation of the effect of B. subtilis R0179 on General  Wellness  and Gastrointestinal Symptoms using Questionnaires", 
            "safety_issue": "No", 
            "time_frame": "6 Weeks"
        }, 
        "reference": [
            {
                "PMID": "16102604", 
                "citation": "Hong HA, Duc le H, Cutting SM. The use of bacterial spore formers as probiotics. FEMS Microbiol Rev. 2005 Sep;29(4):813-35. Epub 2004 Dec 16. Review."
            }, 
            {
                "PMID": "19783474", 
                "citation": "Oelschlaeger TA. Mechanisms of probiotic actions - A review. Int J Med Microbiol. 2010 Jan;300(1):57-62. doi: 10.1016/j.ijmm.2009.08.005. Epub 2009 Sep 23. Review."
            }, 
            {
                "PMID": "18449224", 
                "citation": "Tompkins TA, Hagen KE, Wallace TD, Fillion-Fort\u00e9 V. Safety evaluation of two bacterial strains used in Asian probiotic products. Can J Microbiol. 2008 May;54(5):391-400. doi: 10.1139/w08-022."
            }, 
            {
                "PMID": "21840798", 
                "citation": "Tompkins TA, Xu X, Ahmarani J. A comprehensive review of post-market clinical studies performed in adults with an Asian probiotic formulation. Benef Microbes. 2010 Mar;1(1):93-106. doi: 10.3920/BM2008.1005. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802151"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Microbial diversity measured by denaturing gradient gel electrophoresis (DGGE) profiling\nQuantitative polymerase chain reaction (qPCR) to quantify treatment effects on specific bacteria", 
            "measure": "Evaluation of the Survival of B. Subtilis R0179 and Analyzing the Microbial Diversity in Stool Samples by Participants (Microbiota Study)", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "source": "University of Florida", 
        "sponsors": {
            "collaborator": {
                "agency": "Lallemand Human Nutrition", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}